申请人:Agouron Pharmaceuticals, Inc.
公开号:US05484926A1
公开(公告)日:1996-01-16
HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.
HIV蛋白酶抑制剂可通过化学合成获得,能够抑制或阻止HIV蛋白酶酶的生物活性,导致HIV病毒的复制终止。这些化合物以及包含这些化合物和其他抗病毒剂作为活性成分的制药组合物,适用于治疗感染HIV病毒的患者或宿主,该病毒已知会导致艾滋病。